Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SWKH |
---|---|---|
09:39 ET | 100 | 15.66 |
09:57 ET | 434 | 15.505 |
10:00 ET | 100 | 15.32 |
10:22 ET | 100 | 15.31 |
10:33 ET | 100 | 15.29 |
10:36 ET | 400 | 15.19 |
10:38 ET | 400 | 15.19 |
10:44 ET | 100 | 15.245 |
11:05 ET | 100 | 15.245 |
11:12 ET | 100 | 15.245 |
11:16 ET | 200 | 15.245 |
11:18 ET | 179 | 15.24 |
11:20 ET | 100 | 15.19 |
11:25 ET | 100 | 15.19 |
11:50 ET | 200 | 15.14 |
11:52 ET | 100 | 15.14 |
12:17 ET | 100 | 15.145 |
12:35 ET | 200 | 15.145 |
12:50 ET | 100 | 15.165 |
01:11 ET | 100 | 15.165 |
01:20 ET | 100 | 15.165 |
01:36 ET | 116 | 15.165 |
01:49 ET | 100 | 15.165 |
02:16 ET | 100 | 15.165 |
02:34 ET | 100 | 15.235 |
02:41 ET | 100 | 15.235 |
03:03 ET | 100 | 15.215 |
03:24 ET | 400 | 15.21 |
03:26 ET | 100 | 15.21 |
03:30 ET | 4926 | 15.21 |
03:32 ET | 5000 | 15.21 |
03:33 ET | 200 | 15.21 |
03:35 ET | 100 | 15.215 |
03:37 ET | 100 | 15.215 |
03:44 ET | 4047 | 15.215 |
03:48 ET | 100 | 15.2 |
03:51 ET | 400 | 15.155 |
03:53 ET | 1300 | 15.165 |
03:55 ET | 300 | 15.16 |
03:57 ET | 300 | 15.165 |
04:00 ET | 4095 | 15.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
SWK Holdings Corp | 186.6M | 18.2x | +21.40% |
Terra Income Fund 6 LLC | 195.9M | --- | --- |
MCAP Inc | 129.3M | -0.1x | --- |
Chicago Atlantic BDC Inc | 294.6M | 19.4x | --- |
Multi Ways Holdings Ltd | 7.6M | 3.0x | --- |
American Shared Hospital Services | 20.3M | 5.3x | -11.40% |
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $186.6M |
---|---|
Revenue (TTM) | $42.5M |
Shares Outstanding | 12.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $0.84 |
Book Value | $22.43 |
P/E Ratio | 18.2x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 15.2x |
Operating Margin | 20.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.